HALIFAX, March 7 /PRNewswire-FirstCall/ - MedMira Inc., ("MedMira") (TSX
Venture: MIR, NASDAQ: MMIRF) the global market leader in premium rapid
diagnostic solutions, announced today that it will host a conference call with
analysts to discuss the company's second quarter financial results and provide
a corporate update beginning at 9:00 am EST (10:00 am AST) on Wednesday,
March 8, 2006. MedMira's second quarter financial results were released on
February 16, 2006 and are available on the MedMira website at www.medmira.com.
In order to listen to the conference call, please dial 1-800-814-4861
toll-free anywhere in Canada or the USA, or 1-416-644-3417 in the Toronto
A replay of the call will be available until 23:59 pm EST, Thursday,
March 16, 2006 and may be accessed by dialing 1-877-289-8525 toll-free
anywhere in Canada or the USA, or 1-416-640-1917 in the Toronto area, and
entering the pass code 21180349 followed by the number sign anytime after the
call has ended.
MedMira is the leading global manufacturer and marketer of in vitro flow-
through rapid diagnostic tests. MedMira's tests provide reliable, rapid
diagnosis in just 3 minutes for the detection of human antibodies in human
serum, plasma or whole blood for diseases such as HIV and hepatitis C. The
United States FDA and the SFDA in the People's Republic of China have approved
MedMira's Reveal(R) G2 and MiraWell(R) rapid HIV tests, respectively.
MedMira's Reveal(R) G2 and MiraWell(R) rapid HIV tests are currently used
in clinical laboratories, hospitals, and clinics where professional
counselling and patient treatment are immediately available.
The MiraCare(TM) Rapid HIV Antibody Test is available over-the-counter
(OTC) in pharmacies throughout Hong Kong and Macao Special Administrative
Regions, in the People's Republic of China. MiraCare(TM) is sold through
MedMira's distributor network to pharmacies, hospitals and laboratories in the
MedMira delivers rapid diagnostic solutions to healthcare communities
around the globe. Its corporate offices and manufacturing facilities are
located in Halifax, Nova Scotia, Canada with a representative office in
This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
For more information visit MedMira's website at www.medmira.com.
SOURCE MedMira Inc.